Prospective randomised study of doxorubicin [DC Bead] in the treatment of hepatocellular carcinoma by drug-eluting bead embolisation (PRECISION V).

Trial Profile

Prospective randomised study of doxorubicin [DC Bead] in the treatment of hepatocellular carcinoma by drug-eluting bead embolisation (PRECISION V).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2010

At a glance

  • Drugs Doxorubicin (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRECISION V
  • Sponsors Biocompatibles International
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jun 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 04 Jun 2010 Tolerability results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top